

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to furnish information to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 4

Complete if Known

Application Number	10/600,266
Filing Date	June 20, 2003
First Named Inventor	Fumitoshi Asai
Art Unit	1629
Examiner Name	Leslie A. Royds Draper
Attorney Docket Number	17620-105003

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (If known)			
		2011/0003847	01-06-2011	Doser	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ - Number ⁴ - Kind Code ⁵ (If known)				
		EP 0 555 042	08-11-1993	Tanabe Seiyaku Co., Ltd.		
		EP 1 350 511 A1	10-08-2003	Sankyo Company Limited		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Berge et al., "Pharmaceutical Salts," Journal of Pharmaceutical Sciences, 66(1), pp. 1-19, January 1977	
		Bloom, "Comprehensive Toxicology: Modulation of Platelet Function by Xenobiotics: Toxicologic Implications," (Jakubowski) vol. 4, pp. 247-261, 1997	
		Boneu et al., "Platelet Anti-Aggregating Activity and tolerance of clopidogrel in atherosclerotic patients," <u>Thromb Haemost.</u> , 76(6), pp. 939-43, December 1996.	
		Brown et al., "Comparison of Antiplatelet Activity of Microencapsulated Aspirin 162.5 mg (Caspac XL), with Enteric Coated Aspirin 75 mg and 150 mg in Patients with Atherosclerosis," Blackwell Science Ltd. Br. J. Clin. Pharmacol., 48, pp. 57-62, 1999	
		Budd et al., "The Effectiveness of Low Dose Slow Release Aspirin as an Antiplatelet Agent," Journal of the Royal Society of Medicine, 86, pp. 261-263, May 1993	
		Campo et al., "Poor Responsiveness to Clopidogrel: Drug-Specific or Class-Effect Mechanism," Journal of American College of Cardiology, 50(12), pp. 1132-1137, 2007	
		Chhaya J. Shah, Pharm. D., Curriculum Vitae, May 2006	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the receipt of the document must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 10 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to do (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 4

Complete if Known

Application Number	10/600,266
Filing Date	June 20, 2003
First Named Inventor	Fumitoshi Asai
Art Unit	1629
Examiner Name	Leslie A. Royds Draper
Attorney Docket Number	17620-105003

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Clarke et al., "Suppression of Thromboxane A ₂ But Not of Systemic Prostacyclin by Controlled-Release Aspirin," The New England J. of Medicine, 325(16), pp. 1137-1141, 1991	
		Diener et al., "European Stroke Prevention Study 2. Dipyridamole and Acetylsalicylic Acid in the Secondary Prevention of Stroke," J. of the Neurological Sciences, 143, pp. 1-13, 1996	
		Esato et al., "Satigrel, a New Antiplatelet Agent, Inhibits Platelet Accumulation in Prosthetic Arterial Grafts," Am. J. Surg., 175, pp. 56-60, 1998	
		Figure 2, Food and Drug Administration (FDA) Approval Document for Plavix (Generic Name, Clopidogrel Bisulphate), approved November 17, 1997	
		Gotoh et al., "Cilostazol Stroke Prevention Study: A Placebo-Controlled Double-Blind Trial for Secondary Prevention of Cerebral Infarction," J. of Stroke and Cerebrovascular Diseases, 9(4), pp. 147-157, 2000	
		Ikeda et al., "Pharmacokinetics and Disposition of CD-747, a New Pro-drug ADP-Receptor Antagonist, in Rats and Dogs," Thromb. Haemost., 82, 1999, p. 829, Abstr. 2627	
		Kishi et al., "Ibuprofen Modulates Platelet-Endothelium Interaction Mainly Through Cyclic GMP-Dependent Mechanism," Journal of Cardiovascular Pharmacology, 36(1), pp. 65-70, July 2000	
		Krupinski et al., "The Antithrombotic Effect of Thromboxane Receptor Antagonist HN 11500 on Thrombus Formation in Laser Thrombosis Model and Platelet Function Tests," Acta Haematol. Pol., 25(3), pp. 235-242, 1994, Abstract only	
		Leadbeater et al., "In vitro Aspirin Has Little Additional Anti-Platelet Effect in the Presence of Prasugrel Active Metabolite," Proceedings of the British Pharmacological Society at http://www.pA2online.org/abstracts/vol8issue/abst146P.pdf , December 15, 2010, Abstract only	

Examiner
SignatureDate
Considered

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 909. Draw line through citation if not in conformance and not considered. Include copy of this form with most communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST 10 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is guaranteed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

3

of

4

Complete if Known

Application Number

10/600,266

Filing Date

June 20, 2003

First Named Inventor

Fumitoshi Asai

Art Unit

1629

Examiner Name

Leslie A. Roys Draper

Attorney Docket Number

17620-105003

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Lenz et al., "Aggrenox: A Fixed-Dose Combination of Aspirin and Dipyridamole," The Annals of Pharmacotherapy, 34, pp. 1283-1290, 2000	
		Maruyama et al., "A Randomized Trial of E5510 Versus Aspirin in Patients with Transient Ischemic Attacks: The Japanese E5510 TIA Study-1 (JETS-1) Group," Angiology, 46(11), 999-1008, 1995	
		Mehta et al., "Effects of Pretreatment with Clopidogrel and Aspirin Followed by Long-Term Therapy in Patients Undergoing Percutaneous Coronary Intervention: the PCI-CURE Study," The Lancet, 358, pp. 527-533, August 18, 2001	
		Meiji Seika: Activities Abroad Extended, Bulletin International Abstract, Paris, France, Feb. 1997	
		Milani et al., "Effects of Picotamide, an Antiplatelet Agent, on Cardiovascular Events in 438 Claudicant Patients with Diabetes: a Retrospective Analysis of the ADEP Study," Br. J. Clin. Pharmacol., 42, pp. 782-785, 1996	
		Mousa et al., "Comparative in vitro Efficacy of Different Platelet Glycoprotein IIb/IIIa Antagonists on Platelet-Mediated Clot Strength Induced by Tissue Factor with Use of Thromboelastography: Differentiation Among Glycoprotein IIb/IIIa Antagonists," Arterioscler Thromb Vasc Biol., 20, pp. 1162-1167, 2000	
		PLAVIX® - Committee for Proprietary Medicinal Products European Public Assessment Report (EPAR), The European Agency for the Evaluation of Medicinal Products, revision 2, October 2000	
		The RAPT Investigators, "Randomized Trial of Ridogrel, A Combined Thromboxane A ₂ Synthase Inhibitor and Thromboxane A ₂ /Prostaglandin Endoperoxide Receptor Antagonist, Versus Aspirin as Adjunct to Thrombolysis in patients with Acute Myocardial Infarction," Circulation, 89, pp. 588-595, 1994	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Code of USPTO Patent Documents at 37 CFR 1.801(a) or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is in the (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 422 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to furnish information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 4

Complete if Known

Application Number	10/600,266
Filing Date	June 20, 2003
First Named Inventor	Fumitoshi Asai
Art Unit	1629
Examiner Name	Leslie A. Royds Draper
Attorney Docket Number	17620-105003

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		First Declaration of Professor Stanley Heptinstall in the matter of European Patent No. EP 1350511, in the name of Daiichi Sankyo Company et al., and Opposed by Helm AG, And Ratiopharm GmbH, October 25, 2011	
		Second Declaration of Professor Stanley Heptinstall in the matter of European Patent No. EP 1350511, in the name of Daiichi Sankyo Company, Limited and Ube Industries, Ltd. And Oppositions thereto by Helm AG, Teva Pharmaceutical Industries, Ltd. And Ratiopharm GmbH, October 26, 2011	
		Storey et al., "First Clinical Study of the Novel Platelet ADP Receptor (P ₂ T) Antagonist AR-C69931MX, Assessing Safety, Tolerability and Activity in Patients With Acute Coronary Syndromes," Circulation, Abstract #3745, 1999	
		Swanson et al., "Effect of BMS-18029, A long Acting Thromboxane A2 Receptor Antagonist, on Platelet Function in Healthy Men," Clinical Pharmacology & Therapeutics, 202, PIII-82, February 1994	
		Takai et al., "Hydolytic Profile for Ester-or-Amide-linkage by Carboxylesterases pl 5.3 and 4.5 from Human Liver," Biol. Pharm. Bull., 20(8), pp. 869-873, 1997	
		Todoruk, "Eli Lilly, Daiichi Sankyo's Effient Garners FDA Approval," FirstWord™, retrieved from www.firstwordplus.com , July 10, 2009	
		Varenhorst et al., "Genetic Variation of CYP2C19 Affects Both Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel but Not Prasugrel in Aspirin-Treated Patients with Coronary Artery Disease," Circulation, July 8, 2008	
		Vetrano et al., "Effects of Aspirin or Picotamide, an Antithromboxane Agent, in Combination with Low-Intensity Oral Anticoagulation in Patients with Acute Myocardial Infarction: a Controlled Randomized Pilot Trial," G. Ital. Cardiol., 29(5), pp. 524-528, May 1999, Abstract only	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with most communication to applicant. Applicant's unique citation designation number (optional). ¹ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ² Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 10 if possible. ⁴ Applicant is to place a check mark here if English language. Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.